

## The Obstetrician & Gynaecologist

**[Manuscript title] Present status and advances in bladder pain syndrome: central sensitisation and the urinary microbiome**

**[Running title] BPS: central sensitisation and urinary microbiome**

**[Author names and postnominal initials]**

Ifeoma Offiah PhD MRCOG<sup>1\*</sup>, Rosie Campbell<sup>2</sup>, Anupreet Dua MD MRCOG<sup>3</sup>,  
Luigi Bombieri MD MRCOG<sup>4</sup>, Robert Freeman MD FRCOG<sup>4</sup>

<sup>1</sup>NHR Clinical lecturer and Subspecialty Trainee in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>2</sup>Specialty Trainee in Obstetrics and Gynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>3</sup>Consultant in Obstetrics and Gynaecology and Subspecialist in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>4</sup>Consultant Subspecialist in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the [Version of Record](#). Please cite this article as doi: [10.1111/tog.12807](https://doi.org/10.1111/tog.12807)

This article is protected by copyright. All rights reserved.

\*Correspondence: lfeoma Offiah. Email ifyoffiah@yahoo.co.uk

**Disclosure of interests:**

There are no conflicts of interest.

**Contribution to authorship:**

IO and LB instigated the article. IO and RC researched and wrote the article; LB, AD and RF edited the article. All authors approved the final version.

**[Manuscript title] Present status and advances in bladder pain syndrome: central sensitisation and the urinary microbiome**

**[Running title] BPS: central sensitisation and urinary microbiome**

**[Author names and postnominal initials]**

Ifeoma Offiah PhD MRCOG<sup>1\*</sup>, Rosie Campbell<sup>2</sup>, Anupreet Dua MD MRCOG<sup>3</sup>, Luigi Bombieri MD MRCOG<sup>4</sup>, Robert Freeman MD FRCOG<sup>4</sup>

<sup>1</sup>NHRC Clinical lecturer and Subspecialty Trainee in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>2</sup>Specialty Trainee in Obstetrics and Gynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>3</sup>Consultant in Obstetrics and Gynaecology and Subspecialist in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

<sup>4</sup>Consultant Subspecialist in Urogynaecology, University Hospitals Plymouth NHS Trust, Derriford Road, Plymouth PL6 8DH, UK

## **BPS: central sensitisation and urinary microbiome**

\*Correspondence: Ifeoma Offiah. Email ifyoffiah@yahoo.co.uk

### **Disclosure of interests:**

There are no conflicts of interest.

### **Contribution to authorship:**

IO and LB instigated the article. IO and RC researched and wrote the article; LB, AD and RF edited the article. All authors approved the final version.

### **[Abstract]**

#### **Key Content:**

- Bladder pain syndrome (BPS) presents as a spectrum of urological symptoms with poorly understood pathophysiology. Bladder mucosal injury secondary to low grade sub-clinical infection is a possible trigger, leading to nociceptive upregulation and subsequently, central sensitisation.
- Brain abnormalities associated with BPS suggest that neuropathological brain alterations exist, which may contribute to the perceived pain.

## **BPS: central sensitisation and urinary microbiome**

- Central sensitisation plays a role in the disease pathophysiology via an augmentation in the responsiveness of the central pain signalling neurons.
- The urinary microbiome is implicated as a trigger for the development and maintenance of BPS.
- Future directions to improve treatment strategies include stratification of patients with BPS into subtypes such as peripheral or central disease and investigation of the urinary microbiome and bladder barrier replacement.

### **Learning objectives**

- To update clinicians' knowledge of current research into the urinary microbiome and pain sensitisation in BPS pathophysiology.
- To understand the biodiversity and abundance of urinary microbes and the role of peripheral and central pain sensitisation, which will help identify future management techniques for BPS.

### **Ethical issues:**

- What are the consequences of long-term antibiotics use for BPS management on bacterial resistance?

### **[Heading 1] Bladder pain syndrome as a chronic pain state**

## **BPS: central sensitisation and urinary microbiome**

Though unpleasant, pain is an important facet for survival, forewarning the body of potential (based on a memory of previous pain experience) or actual tissue harm. Pain sensation thus confers protection and is useful for the prevention of further harm.

Tissue injury promotes many adaptations, leading to the recruitment of inflammatory and pain mediators, such as chemokines and cytokines, to the site of damage. The role of these recruited mediators is to aid in tissue repair. In addition, they activate sensory afferents at the site of tissue damage thus triggering the development of pain hyperalgesia. Hyperalgesia, also known as hypersensitivity, is an abnormally increased sensitivity to pain: painful stimuli are experienced as more painful than normal. Hyperalgesia helps with the healing process by ensuring that physical contact with the injured area is reduced while tissue repair continues. Primary hyperalgesia, which is pain at the direct site of injury, as well as secondary hyperalgesia in the surrounding tissue, is thus an important part of the body's defence mechanism. These changes are usually temporary. Abnormal persistence of these adaptations following injury can permit changes that contribute to the development of chronic pain states.

The pain itself becomes the primary clinical problem, neither protecting nor supporting tissue healing. Bladder pain syndrome (BPS) is one such chronic pain condition, in which pain is the overriding condition.

BPS, also known as interstitial cystitis (IC), is defined as a spectrum of urological symptoms characterised by persistent or recurrent chronic pelvic pain, pressure or discomfort, which is perceived to be related to the urinary bladder and is accompanied by at least one other urinary symptom, such as urinary urgency or frequency.<sup>1</sup> It is a disease of unknown aetiology, with a poorly understood pathophysiological mechanism. BPS is more common in women than men, with a prevalence rate of 2–

## **BPS: central sensitisation and urinary microbiome**

6%.<sup>2</sup> The disease phenotype is varied; some patients display a mild form of the disease and treatment can be undertaken in the outpatient setting, whereas others have a debilitating disease, requiring repeated hospital visits. The treatment objective is therefore focused on restoring function, preventing relapse of symptoms and improving quality of life (Table 1).<sup>2,3</sup> A multidisciplinary approach to management is key to success, where patients are reviewed in dedicated clinics, including specialists in psychology, pain management, urology and urogynaecology.

The mechanisms of pain in BPS are poorly understood. The bladder mucosa is lined by a protective proteoglycan layer. Proteoglycans are large, heavily glycosylated protein moieties, composed of a protein core and glycosaminoglycan (GAG) side chains. They densely cover the luminal surface of the bladder wall, forming a hydrophobic barrier that prevents the permeation of bacteria, proteins and urinary solutes into the underlying muscles and nerves.<sup>4</sup> In the bladder, the intact proteoglycan molecule provides the immediate interface between urine and the bladder wall and is a critical regulator of bladder permeability.<sup>5</sup> This layer may be dysfunctional in some patients with BPS.<sup>6</sup> Pentosan polysulfate sodium (Elmiron®), which has a similar structure to GAGs, is therefore used as a treatment for BPS, as it helps to replace the damaged urothelial barrier in patients with BPS (Table 1).

The precise trigger leading to the development of BPS remains unknown. However, it is possible that bladder injury by irritant chemicals, radiation, blunt trauma, childbirth, infection, urologic instrumentation or surgery, triggers the release of inflammatory mediators, leading to disruption of the protective mucosal proteoglycan barrier.<sup>7,8</sup> Ketamine, a dissociative general anaesthetic that is occasionally abused as a recreational drug, can cause a form of cystitis known as ketamine cystitis. The

## **BPS: central sensitisation and urinary microbiome**

Accepted Article

symptoms experienced by patients with ketamine cystitis are very similar to BPS. Patients develop pain and bladder ulceration. Recreational use of this drug must be ruled out during assessment of patients presenting with bladder pain.<sup>9</sup> Resident and recruited immune cell proteins, such as chemokines and cytokines, as well as toxic urinary solutes, permeate the damaged mucosal barrier leading to the depolarisation of sensory afferents (Figure 1).<sup>10</sup> These immune cell proteins induce hyperalgesia by increasing the number of nociceptor channels on the afferent nerve surface membrane. Nociceptors are pain signalling neurons, which send signals of actual or potential tissue damage to the spinal cord and brain. They are triggered by chemical, thermal and mechanical stimuli. Their activation by immune cell proteins leads to the peripheral release of neurotransmitters involved in the transmission of pain signals, namely substance P and calcitonin gene-related peptide (CGRP). This is followed by the development of neuropathic pain. The trigger for peripheral and central sensitisation is thus unleashed.

### **[Heading 1] Central sensitisation and BPS**

Since 2000, research into the pathophysiology of BPS had started to investigate beyond the bladder to find other unexploited treatment targets for this syndrome. The role of central sensitisation in BPS was thus further evaluated. Central sensitisation is the “augmentation of responsiveness of central pain-signalling neurons to inputs from low-threshold mechanoreceptors”.<sup>11,12</sup>

Central sensitisation is an umbrella term used to describe a group of disorders sharing common symptoms with no underlying pathology, but with pain being the leading



## **BPS: central sensitisation and urinary microbiome**

feature. These conditions are known as central sensitivity syndromes. They include conditions such as fibromyalgia, irritable bowel syndrome (IBS), temporomandibular joint disorder, chronic fatigue syndrome, vulvodynia and headaches.<sup>13</sup> Other pelvic pain symptoms, often thought to be associated with prolapse, especially dragging and vaginal pain, can be caused by central sensitisation.<sup>14</sup> These conditions are mutually associated, with the presence of one syndrome accompanying another.<sup>15</sup> BPS is associated with central sensitivity syndromes such as fibromyalgia, IBS, vulvodynia and migraines: these are a group of medically indistinct syndromes in which central sensitisation plays a significant role.<sup>16</sup>

The increase in central excitability is normally triggered by damage to peripheral tissues and subsequent release of nociceptive mediators such as glutamate, and activation of peripheral nociceptors. Once activated, these low-threshold peripheral nociceptors form synaptic connections with neurons within the central nervous system (CNS) causing pain.<sup>13,17,18</sup> Persistence of the noxious activation, such as a low-grade chronic infection in the bladder, can cause upregulation in the number and activity of peripheral nociceptors, which consequently elicits an increase in the responsiveness of the CNS neurons. Thus, normal sensory inputs such as touch or heat, begin to produce abnormal painful responses, and clinical pain syndromes (such as tactile allodynia and hyperalgesia) are manifest (Figure 2). In BPS, bladder filling, which is normally an innocuous stimulus, causes pain. Although the pain feels like it originates in the periphery, it is a manifestation of abnormal sensory processing within the CNS.

Factors predisposing to central sensitisation are varied. Direct injury to CNS structures secondary to insults such as infection, trauma or ischemia can precipitate central sensitisation. However, the mechanisms by which peripheral injury leads to central

## **BPS: central sensitisation and urinary microbiome**

sensitisation are more complex. The patient phenotype and their psychosocial and environmental influences are important.<sup>19</sup> BPS is commonly associated with depression and anxiety.<sup>20,21</sup>

Compared with controls, patients with BPS have a significantly lower pain threshold, with segmental mechanical hyperalgesia thought to be associated with central sensitisation.<sup>22,23</sup> Patients with BPS have significantly increased volumes in several regions of the brain, including the primary somatosensory cortex, compared with controls; this is thought to have a role in increased pain sensitivity.<sup>24</sup> A study by Offiah and colleagues<sup>25</sup> supports this finding; they reported resistance to intravesical lidocaine in BPS patients with more severe bladder pain and other associated central sensitivity syndromes.

Chronic pain neuroimaging studies have demonstrated unique changes in brain anatomy and function. Khavari and Boone<sup>26</sup> reported on structural anatomical and regional areas of abnormality in the CNS of women with BPS compared with controls. These abnormalities relate to aspects of the patients' mood, quality of life and daily functioning and are thought to be involved in chronic pain maintenance.<sup>26</sup>

### **[Heading 1] Use of central modifying drugs in BPS**

Amitriptyline is a tricyclic antidepressant commonly used to treat neuropathic pain. It suppresses the re-uptake of noradrenaline and serotonin at presynaptic nerve endings of the central and peripheral nervous system. This leads to sedation caused by an antihistamine reaction in the CNS. It has a rapid onset of analgesic effect at higher doses. Studies have shown that whether used alone or in combination with other

## **BPS: central sensitisation and urinary microbiome**

medication, amitriptyline is an alternate management strategy for patients diagnosed with BPS: success rates are reported in 45.5–66.0% of patients.<sup>27,28,29</sup> Use is limited to lower doses (mean dose = 55 mg, range 12.5–150.0 mg) owing to significant side-effects, such as dry mouth and weight gain, noted by 84% of patients at the higher, more effective doses.<sup>28</sup>

Gabapentinoids are both peripheral and centrally acting ligands that lead to blockade of calcium channels. Though not a licenced treatment for BPS, they are occasionally considered in this patient group because of their therapeutic effect on visceral inflammatory and neuropathic pain.<sup>30</sup> There are currently no clinical data evaluating efficacy in BPS. Side effects include suicidal ideation, respiratory depression, withdrawal and dependence.

### **[Heading 1] Other BPS management approaches focussed on central sensitisation**

In cases such as BPS, where central sensitisation is thought to be important in the pain pathophysiology, peripheral approaches to management may prove insufficient, as the root driver of pain remains unaddressed. Central neuromodulation may be more effective for symptom control. Peripheral neuromodulation, including sacral nerve stimulation and posterior tibial nerve stimulation, as well as central neuromodulation techniques are alternate management strategies that may be considered for the management of chronic pain syndromes recalcitrant to conventional peripheral treatment approaches. Studies have shown clinically significant improvements in up to 50% of patients.<sup>2,31</sup>

***Heading 2] Peripheral neuromodulation***

Peripheral neuromodulation, such as posterior tibial nerve stimulation (PTNS) and sacral nerve stimulation (SNS) can lead to improvement of symptoms in patients with chronic pelvic pain and BPS. Their mechanism of action is poorly understood; however, they primarily work on the peripheral nervous system and do not target central pathways. One proposed mechanism of action is the 'gate control theory of pain'. Stimulation of the peripheral nociceptor with a non-noxious stimulus closes the 'gates' to painful stimuli, therefore blocking ascending pain signals to the central nervous system.<sup>32</sup> Other suggested mechanisms include a reduction of pelvic floor hypertonicity, a reduction of inflammatory chemokine levels and stimulation of spinal opioid pathways.<sup>33</sup>

***[Heading 2] Deep brain stimulation***

Deep brain stimulation (DBS) is a neurosurgical treatment that involves placing neurostimulators into specific anatomical regions of the brain. Septal and medial forebrain stimulation has analgesic effects in acute and chronic pain patients.<sup>34,35</sup> Peripheral effects of stimulation include analgesia, mild euphoria, feelings of warmth, well-being and relaxation. A significant improvement is seen in urinary incontinence and frequency in Parkinson's disease patients following DBS of the subthalamic nuclei in both men and women.<sup>36</sup> DBS has yet to be used specifically for the management of BPS, but the results of these studies are encouraging.

## **BPS: central sensitisation and urinary microbiome**

### ***[Heading 2] Repetitive transcranial magnetic stimulation***

Repetitive transcranial magnetic stimulation (r-TMS) is a non-invasive therapy that uses magnets to induce a transient electrical current in the cortex underlying the magnetic coil. It works by depolarisation of the surrounding cortical neurones, resulting in a reorganisation of pathological neuronal networks. A randomised, double-blinded, sham-controlled study to investigate the use of r-TMS in treating BPS was performed.<sup>37</sup> In this study, patients with pharmacological treatment-resistant BPS underwent cyclical treatment of either real r-TMS or sham r-TMS (placebo). They showed a significant reduction in pain score following real r-TMS compared to sham. Also noted was an improvement in lower urinary tract symptoms, most notably bladder emptying, and an improvement in quality of life. This study, as well as a case report by Nizard and colleagues,<sup>38</sup> which describes improvement of BPS symptoms in a woman following high-intensity, low-frequency r-TMS of the pre-frontal cortices, demonstrates the positive effects of central pain modulation in patients with centralised BPS phenotypes.

### **[Heading 1] Urinary microbiome**

Until recently, urine was considered sterile in the healthy subject and the presence of bacteria in the urine was associated with a urinary tract infection (UTI). However, in the early 2010s, use of high-throughput molecular DNA sequencing of bacterial 16S rRNA genes enabled the analysis of complex microbial communities inhabiting the human urinary tract.<sup>39,40</sup> It is now widely accepted that the bladder has a healthy bacterial flora: the urinary microbiome.

## **BPS: central sensitisation and urinary microbiome**

Microbiome is a term used to define the combined community of commensal, symbiotic and pathogenic microorganisms that exist throughout the human body. Each body site has a specific microbiota, dependent on the individuals' habits, geographical location and genetic make-up. The microbiome can be vital in maintaining health, but when it becomes disrupted it enters a state of 'dysbiosis,' which may contribute to disease. An imbalance of the gastrointestinal tract microbiota, for example, has been associated with inflammatory bowel disease, asthma and obesity. It is therefore plausible that dysbiosis in the bladder microbiome could be responsible for chronic disease states. Studies detailing the composition of the urinary microbiome and linking the healthy urinary microbiome with health, and urinary dysbiosis with disease, are therefore attracting much interest but are still in their infancy.

The urinary microbiome alters in response to various factors, such as health and disease, as well as menopausal status.<sup>41</sup> In healthy females, the most abundant genera of bacteria found in the bladder include *Lactobacillus*, *Prevotella*, *Streptococcus* and *Gardnerella*.<sup>41,42</sup> To further explore the role of infection in BPS, Warren and colleagues<sup>43</sup> investigated urine samples of women within a year of the onset of BPS diagnosis. They found that bacteriuria was present at the onset of BPS in some women, hinting at a possible disease pathogenesis.

### **[Heading 1] Use of antibiotics in the management of BPS: success or failure?**

Secondary to this alteration in the urinary microbiome, there has been a refocus on the use of long-term, low-dose antibiotics for the management of BPS and its associated lower urinary tract symptoms (LUTS).

## **BPS: central sensitisation and urinary microbiome**

At first, studies into the use of antibiotics for BPS management appeared discouraging. A randomised, double-blind, placebo-controlled trial of antibiotics in patients with BPS reported a nonsignificant overall improvement in pain and urgency symptoms following antibiotic treatment compared with placebo.<sup>44</sup> Antibiotics used in this study were rifampicin plus a sequence of doxycycline, erythromycin, metronidazole, clindamycin, amoxicillin and ciprofloxacin for 3 weeks each. These findings were echoed by a more recent study, which reported no improvement in questionnaire scores following treatment of bacteriuria with a regime of 3–5 days of either nitrofurantoin, trimethoprim or fluoroquinolone in BPS patients.<sup>45</sup> The results did, however, show a nonsignificant decrease in visual analogue scores (VAS) for pain following antibiotic treatment. These studies suggest that neither a long nor short course of antibiotics is a major advance in the management of BPS as their use does not lead to a resolution of pain or LUTS.

Further studies have demonstrated a reduction in bacterial culture levels and improvement in BPS LUTS following treatment with antibiotics (Table 2).<sup>46–50</sup> These studies suggest that use of low-dose, long-term antibiotics leads to symptom improvement and are a possible treatment strategy for the management of patients with chronic BPS pain and LUTS. However, none of these are randomised or level one studies. The studies have differing study populations, methods of BPS diagnosis, assessment of improvement and questionnaires used. In addition, no comparison of the efficacy of antibiotic treatment has been made with other established treatments for BPS. If considering antibiotic use for BPS management, it is prudent to pay attention to reported side effects and to consider an alternate antibiotic, duration of use, dosage and treatment regimen. Implications for antibiotic resistance should also be considered.

## **BPS: central sensitisation and urinary microbiome**

These most recent papers on antibiotic success in BPS have been published since the release of the Royal College of Obstetricians and Gynaecologists' 2016 Green-top guideline on 'Management of bladder pain syndrome'. This guideline states that "long-term antibiotics ... are not recommended for BPS."<sup>2</sup> The effect of antibiotics on this complex syndrome deserves further research, as a review of the evidence seems to indicate that antibiotics might indeed have a role to play in disease management.

### **[Heading 1] Future directions**

Research into BPS over the last 30 years has resulted in a new understanding of the bladder urothelium and the impact of urothelial injury on the symptoms experienced by patients with BPS. Research continues into discovering new biomarkers to better subtype patients. The stratification of patients into BPS subtypes is important to determine the treatment modalities or targets that would be most effective. Several novel therapies have shown promise in small clinical trials. These include monoclonal antibodies, which target the overexpression of immune-mediated cytokines, and cannabinoids, frequently successfully used in other chronic pain conditions.<sup>51</sup> iAluRil®, which contains hyaluronic acid and chondroitin sulfate, has shown efficacy in the management of recurrent UTIs. In a cohort study of 157 patients with recurrent UTIs,<sup>52</sup> a course of four instillations over four consecutive weeks, followed by monthly instillations for 5 months led to a significant reduction in UTI frequency and improvement in patient symptoms and quality of life. By replenishing the GAG layer, this medication – already in use for BPS patients – may protect the underlying sensory nerves and prevent the onset or break the cycle of central sensitisation in patients with BPS. Future research is needed to examine this hypothesis.



**[Heading 1] Conclusion**

Bladder pain syndrome is a complex pain condition, which probably involves malfunctions of both the peripheral and central nervous systems. Treatment is aimed at improving quality of life and preventing relapse. A multimodal approach to treatment, involving lifestyle modification and pharmacological therapy targeting both the bladder peripherally and the CNS, is recommended. Low-dose, long-term antibiotic therapy may be effective after treatment failure with other agents in alleviating symptoms. A multidisciplinary approach to management is key to success.

**[Heading 1] References**

1. Doggweiler R, Whitmore KE, Meijlink JM, Drake MJ, Frawley H, Nordling J, et al. A standard for terminology in chronic pelvic pain syndromes: a *report from the chronic pelvic pain working group of the international continence society*. *Neurourol Urodyn* 2017;36:984–1008.
2. Trilapur SA, Birch JV, Carberry CL, Khan KS, Latthe PM, Jha S. Management of bladder pain syndrome. *BJOG* 2016;124:e46–72.
3. Hanno PM, Erickson DA, Moldwin RM, Faraday M. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. *J Urol* 2015;193:1545–2553.
4. Hurst RE. A deficit of proteoglycans on the bladder urothelium in interstitial cystitis. *Eur Urol* 2003;2:10–3.

## **BPS: central sensitisation and urinary microbiome**

5. Parsons CL, Boychuk D, Jones S, Hurst R, Callahan H. Bladder surface glycosaminoglycans: an epithelial permeability barrier. *J Urol* 1990;143:139–42.
6. Hurst RE, Meerveld BG, Wisniewski AB, VanGordon S, Lin H, Kropp BP, et al. Increased bladder permeability in interstitial cystitis/painful bladder syndrome. *Transl Androl Urol* 2015;4:563–71.
7. Keay SK, Birder LA, Chai TC. Evidence for bladder urothelial pathophysiology in functional bladder disorders. *Biomed Res Int* 2014;2014:865463.
8. Graham E, Chai TC. Dysfunction of bladder urothelium and bladder urothelial cells in interstitial cystitis. *Curr Urol Rep* 2006;7:440–6.
9. Jhang JF, Hsu YH, Kuo HC. Possible pathophysiology of ketamine-related cystitis and associated treatment strategies. *Int J Urol* 2015;22:816–25.
10. Offiah I, Didangelos A, Dawes J, Cartwright R, Khullar V, Bradbury EJ, et al. The expression of inflammatory mediators in bladder pain syndrome. *Eur Urol* 2016;70:283–90.
11. Mendell LM. Constructing and deconstructing the gate theory of pain. *Pain* 2014;155:210–6.
12. Wall PD, McMahon SB, Koltzenburg M. *Wall and Melzack's textbook of pain*. 5th ed. Philadelphia: Elsevier/Churchill Livingstone; 2006.
13. Yunus, MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. *Curr Rheumatol Rev* 2015;11:70–85.
14. Vij M, Davies A, Dua A, Freeman R. The proportion of women with central sensitivity syndrome in gynecology outpatient clinic (GOPDs). *Int Urogynecol J* 2019;30:483–8.

## **BPS: central sensitisation and urinary microbiome**

15. Tietjen GE, Brandes JL, Peterlin BL, Eloff A, Dafer RM, Stein MR, et al., Allodynia in migraine: association with comorbid pain conditions. *Headache* 2009;49:1333–44.
16. Birder LA. Pathophysiology of interstitial cystitis. *Int J Urol* 2019;26:12–5.
17. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* 2011;152 3 Suppl:S2–15.
18. Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. *J Pain* 2009;10:895–926.
19. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. *Front Biosci (Landmark Ed)* 2009;14:5291–338.
20. Offiah I, McMahon S, O'Reilly B. Interstitial cystitis/bladder pain syndrome: diagnosis and management. *Int Urogynecol J.* 2013;24:1243–56.
21. Grundy L, Caldwell A, Brierley SM. Mechanisms underlying overactive bladder and interstitial cystitis/painful bladder syndrome. *Front Neurosci* 2018;12:931.
22. Lai HH, Gardner V, Ness TJ, Gereau RW. Segmental hyperalgesia to mechanical stimulus in interstitial cystitis/bladder pain syndrome: evidence of central sensitization. *J Urol* 2014;191:1294–9.
23. Sanses T, McCabe P, Zhong L, Taylor A, Chelimsky G, Mahajan S, et al. Sensory mapping of pelvic dermatomes in women with interstitial cystitis/bladder pain syndrome. *Neurourol Urodyn* 2018;37:458–65.
24. Kairys AE, Schmidt-Wilcke T, Puiu T, Ichesco E, Labus JS, Martucci K, et al. Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome. *J Urol* 2015;193:131–7.

## **BPS: central sensitisation and urinary microbiome**

25. Offiah I, Dilloughery E, McMahon SB, O'Reilly BA. Prospective comparative study on the effects of lidocaine on urodynamic and sensory parameters in bladder pain syndrome. *Int Urogynecol J* 2019;30:1293–301.
26. Khavari R, Boone T. Imaging: CNS changes in Interstitial cystitis/ painful bladder syndrome. *Nat Rev Urol* 2015;12:365–6.
27. Lusty A, Kavalier E, Zakariasen K, Tolls V, Nickel JC. Treatment effectiveness in interstitial cystitis/bladder pain syndrome: do patient perceptions align with efficacy-based guidelines? *Can Urol Assoc J* 2018;12:E1–5.
28. Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. *Aktuelle Urol* 2010;41:S61–5.
29. Foster HE, Hanno PM, Nickel JC, Payne CK, Mayer RD, Burks DA, et al. Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome. *J Urol* 2010;183:1853–8.
30. Sekiguchi F, Tsubota M, Kawabata A. Involvement of voltage-gated calcium channels in inflammation and inflammatory pain. *Biol Pharm Bull* 2018;41:1127–34.
31. Roy H, Offiah I, Dua A. Neuromodulation for pelvic and urogenital pain. *Brain Sci* 2018;8:180.
32. Rahnama'i MS, Marcelissen T, Apostolidis A, Veit-Rubin N, Schurch B, Cardozo L, et al. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think tank, Bristol. *Neurourol Urodyn* 2018;37:S99–107.
33. Marcelissen T, Jacobs R, van Kerrebroeck P, de Wachter S. Sacral neuromodulation as a treatment for chronic pelvic pain. *J Urol* 2011;186:387.

## **BPS: central sensitisation and urinary microbiome**

34. Keifer OP Jr, Riley JP, Boulis NM. Deep brain stimulation for chronic pain: intracranial targets, clinical outcomes, and trial design considerations. *Neurosurg Clin N Am* 2014;25:671–92.
35. Bittar RG, Kar-Purkayastha I, Owen SL, Bear RE, Green A, Wang SY, et al. Deep brain stimulation for pain relief: a meta-analysis. *J Clin Neurosci* 2005;12:515–9.
36. Witte LP, Oderkerken VJ, Boel JA, Schuurman PR, Gerbrandy-Schreuders LC, de Bie RM, et al. Does deep brain stimulation improve lower urinary tract symptoms in Parkinson's disease? *Neurourol Urodyn* 2018;37:354–9.
37. Cervigni M, Onesti E, Ceccanti M, Gori MC, Tartaglia G, Campagna G, et al. Repetitive transcranial magnetic stimulation for chronic neuropathic pain in patients with bladder pain syndrome/ interstitial cystitis. *Neurourol Urodyn* 2018;37:2678–87.
38. Nizard J, Esnault J, Bouche B, Suarez Moreno A, Lefaucher JP, Nguyen JP. Long-term relief of painful bladder syndrome by high-intensity, low frequency repetitive transcranial magnetic stimulation of the right and left dorsolateral prefrontal cortices. *Front Neurosci* 2018;12:925.
39. Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh M-J, et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. *J Transl Med* 2012;10:174.
40. Wolfe AJ, Toh E, Shibata N, Rong R, Kenton K, Fitzgerald MP, et al. Evidence of uncultivated bacteria in the adult female bladder. *J Clin Microbiol* 2012;50:1376–83.

## **BPS: central sensitisation and urinary microbiome**

41. Bhide A, Tailor V, Khullar V. Interstitial cystitis/ bladder pain syndrome and recurrent urinary tract infection and the potential role of the urinary microbiome. *Post Reprod Health* 2020;26:87–90.
42. Bersamelli M, Santoni M, Ticinesi A, Buti S. The urinary microbiome and anticancer immunotherapy: the potential hidden role of uncultured microbes. *Target Oncol* 2019;14:247–52.
43. Warren JW, Brown V, Jacobs S, Home L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. *Urology* 2008;71:1085–90.
44. Warren JW, Horne LM, Hebel JR, Marvel RP, Keay SK, Chai TC. Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. *J Urol* 2000;163:1685–8.
45. Nickel JC, Shoskes DA, Irvine-Bird K. Prevalence and impact of bacteriuria and/or urinary tract infection in interstitial cystitis/painful bladder syndrome. *Urology* 2010;76:799–803.
46. Zhang QH, Shen XC, Zhou ZS, Chen ZW, Lu GS, Song B. Decreased nanobacteria levels and symptoms of nanobacteria-associated interstitial cystitis/painful bladder syndrome after tetracycline treatment. *Int Urogynecol J* 2010;21:103–9.
47. Nickel JC, Irvine-Bird K, Jianbo L, Shoskes DA. Phenotype directed management of interstitial cystitis/bladder pain syndrome. *Urology* 2014;84:175–9.
48. Swamy S, Barcella W, De Iorio M, Gill K, Khasriya R, Kupelian AS, et al. Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: what should we do? *Int Urogynecol J* 2018;29:1035–43.

## **BPS: central sensitisation and urinary microbiome**

49. Aydogan TB, Gurpinar O, Eser OK, Mathyk BA, Ergen A. A new look at the etiology of interstitial cystitis/ bladder pain syndrome: extraordinary cultivations. *Int Urol Nephrol* 2019;51:1961–7.
50. Swamy S, Kupelian AS, Khasriya R, Dharmesena D, Toteva H, Dehpour T, et al. Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria and negative urinalysis. *Int Urogynecol J* 2019;30:409–14.
51. Colemeadow J, Sahai A, Malde S. Clinical management of bladder pain syndrome/interstitial cystitis: a review on current recommendations and emerging treatment options. *Res Rep Urol* 2020;12:331–43.
52. Cicione A, Cantiello F, Ucciero G, Salonia A, Torella M, De Sio M, et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. *Can Urol Assoc J* 2014;8:E721–7.

### **Disclosure of interests:**

No conflicts of interest to disclose.

**[Heading 1] Figure legends**

## **BPS: central sensitisation and urinary microbiome**

**Figure 1. Schematic of barrier disruption in BPS.** In an intact bladder, the proteoglycan molecules and their attached glycosaminoglycans (GAGs) form a hydrophobic layer, thus preventing the permeation of urinary solutes to the underlying epithelial cells; the afferent fibres remain protected. Damage to the proteoglycan molecules through deglycosylation of the GAG side chains or complete proteoglycan loss leads to an ineffective barrier. Toxic urinary solutes pass through the normally impermeable barrier depolarising the underlying nerve.  $K^+$  = potassium.

**Figure 2. Central sensitisation.** The normal pain response curve is shifted to the left with central sensitisation. As a consequence, typically innocuous stimuli are deemed painful (allodynia) and noxious stimuli are more painful (hyperalgesia). These are two of the main features of central sensitisation. VAS = Visual analogue scale: numerical 11-point pain scale from 0, which denotes maximal pain threshold.



## BPS: central sensitisation and urinary microbiome

**Table 1.** Management of bladder pain syndrome (BPS). A combination of conservative management with behavioural modification and physical therapy alongside pharmacotherapy is crucial for the successful management of BPS.

<b>Approach</b>	<b>Treatment/ course of action</b>	<b>Rationale</b>		
Lifestyle modification	Dietary modification	Avoid caffeinated beverages, alcohol, citrus fruits and juices, spicy foods, tomatoes, carbonated drinks, chocolate, as these are irritants to the bladder		
	Avoid constipation	Can worsen bladder symptoms		
	Smoking cessation	Nicotine is a bladder irritant		
	Avoidance of UTI	Increase water intake as concentrated urine can irritate the bladder		
	Bladder training	Avoid frequent micturition 'just in case' to prevent bladder shrinkage		
<b>Oral therapies</b>	<b>Treatment</b>	<b>Method of action</b>	<b>Effect on bladder</b>	<b>Side effects</b>

**BPS: central sensitisation and urinary microbiome**

	Elmiron® (pentosan polysulphate)	Replacement of urothelial barrier	Analgesic effect	Retinal pigmentation
	Anticholinergics	Increased bladder capacity and reduced detrusor contractions	Controls frequency, urgency and urinary incontinence	Dry eyes, dry mouth, constipation
	Analgesia: Amitriptyline	Tricyclic antidepressant	Bladder relaxation at low doses, analgesic with higher doses	Nausea, blurred vision, skin rash and constipation or diarrhoea
	Antibiotics	Low-dose long-term antibiotic use may lead to symptoms improvement		
<b>Intravesical medication</b>	Cystistat®	Bladder mucosal GAG replacement therapy providing analgesic effect		
	iAluRil®	Bladder mucosal GAG replacement therapy providing analgesic effect		

## BPS: central sensitisation and urinary microbiome

	Intravesical botulinum toxin A	Botulinum toxin bladder injections inhibits acetylcholine release resulting in temporary flaccid muscle paralysis
<b>Bladder distention</b>	Cystoscopy and hydrodistention	Allows confirmation of diagnosis  Low-pressure hydrodistention provides relief of frequency and urgency
<b>Neuromodulation</b>	Posterior tibial nerve stimulation	Fine needle electrode is inserted at the ankle to stimulate the tibial nerve  Weekly sessions for an average of 12 weeks is required
	Sacral nerve stimulation	Implanted nerve device for stimulation of the sacral nerve  Used for the treatment of severe urgency, frequency, and urinary retention

Further detailed guidance can be obtained from the AUA and RCOG Guideline<sup>2,3</sup>. GAG = glycosaminoglycans; UTI = urinary tract infection

**Table 2.** Studies detailing results of antibiotic treatment response in patients with BPS or painful LUTS. Treatment led to resolution of symptoms.

<b>Author; year</b>	<b>Study type</b>	<b>Patients; number</b>	<b>Antibiotic treatment</b>	<b>Assessment questionnaires</b>	<b>Findings</b>
Zhang; 2009 <sup>44</sup>	Cross- section al	IC/BPS; n = 27	Tetracycli ne: intravesic al and oral x 3 months	O’Learly Sant symptom and problem index; Pain, urgency and frequency symptom scale.	Reduction in nano- bacterial levels with associated reduction in severity of symptoms
Nickel; 2014 <sup>45</sup>	Cross- section al	BPS; n = 93	Not specified	IC symptom and problem index; Pain, urgency and frequency symptom scale; Visual analogue scale of pain, frequency and urgency: 0–10.	Individualised phenotype directed treatment, including antibiotics for bacteriuria, demonstrated a significant clinical improvement in symptoms


**BPS: central sensitisation and urinary microbiome**

Swarmy ; 2018 <sup>46</sup>	Case series	Chronic LUTS and pyuria including IC/BPS; n = 624	Nitrofurantoin, trimethoprim and cefalexin x 14 days, repeated for 12 weeks until no symptomatic deterioration after antibiotic withdrawal	Patient global impression of improvement scale	Reduction in LUTS, 24-hour frequency, urinary urgency, lower urinary tract pain, voiding symptoms and pyuria.
Aydogan; 2019 <sup>47</sup>	Case series	IC/BPS; n = 26	Oral fluoroquinolones or cefuroxime	O'Leary Sant symptom and problem index	Reduction in median symptom and problem index scores


## BPS: central sensitisation and urinary microbiome

Swarmy ; 2019 <sup>48</sup>	Cross sectional	Painful LUTS and microscopic pyuria; n = 1035: 221 had unplanne d treatment cessation	Cefalexin, trimethopr im and nitrofurant oin: until optimal symptom control	Symptom score <sup>50</sup>	90% of patients with unplanned discontinuation of long-term antibiotic treatment reported a flare of LUTS and deterioration in symptoms  This was followed by recovery with re-instatement
-----------------------------	-----------------	---	---	-----------------------------	--

BPS = bladder pain syndrome; IC = interstitial cystitis; LUTS = lower urinary tract symptoms;



tog\_12807\_tog-20-0088-fig-001\_v2.0.eps



tog\_12807\_tog-20-0088-fig-002\_v2.0.eps